A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Clinical Trial Details

This clinical trial is for men and women with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) to evaluate the safety and effectiveness of ELA026.

In this study, ELA026 will be given intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last about 3 years. Participants will be admitted to the hospital at the start of the study during the administration of ELA026.

Key Eligibility:

Open to men and women above the age of 18 who have been diagnosed with treatment naive Secondary Hemophagocytic Lymphohistiocytosis (sHLH).
Participants must not have refractory sHLH, meaning your SHLH does not respond to treatment.

Detailed eligibility will be reviewed when contacting the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Devonie Manzano, RN
212-746-7117
dgm4004@med.cornell.edu

Primary Investigator(s)

Justin Kaner, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2509029323

ClinicalTrials.gov:

NCT05416307

Status

Open to Enrollment

Age Group

Adult

Disease

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)